Suzanne M Garland1, Alyssa M Cornall2, Julia M L Brotherton3, John D Wark4, Michael J Malloy3, Sepehr N Tabrizi5. 1. Department of Microbiology & Infectious Diseases, Royal Women's Hospital, Locked Bag 300, Parkville, Vic 3052, Australia; Murdoch Children's Research Institute, 50 Flemington Road, Parkville 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville 3052, Australia. Electronic address: suzanne.garland@thewomens.org.au. 2. Murdoch Children's Research Institute, 50 Flemington Road, Parkville 3052, Australia. 3. VCS Registries, Victorian Cytology Service Ltd., Level 6, 176 Wellington Parade, East Melbourne 3002, Australia; School of Population and Global Health, University of Melbourne, Parkville 3052, Australia. 4. University of Melbourne Department of Medicine, Australia; Bone and Mineral Medicine, Royal Melbourne Hospital, Parkville, Vic. 3050, Australia. 5. Department of Microbiology & Infectious Diseases, Royal Women's Hospital, Locked Bag 300, Parkville, Vic 3052, Australia.
Abstract
OBJECTIVES: The VACCINE [Vaccine Against Cervical Cancer Impact and Effectiveness] study evaluated the prevalence of quadrivalent vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst young women of vaccine-eligible age. METHODS: Between October 2011 - June 2015, women aged 18-25 years from Victoria, Australia, were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire and provided a self-collected vaginal swab for HPV DNA detection and genotyping (Linear Array HPV genotyping assay). Self-reported HPV vaccination details were verified with the National HPV Vaccination Program Register (NHVPR). RESULTS: Of 1223 who agreed to participate, 916 (74.9%) completed the survey and, for 1007 (82.3%) sexually-active participants, 744 (73.9%) returned the self-collected swab, of which 737 contained detectable DNA. 184/737 (25.0%) were positive for HPV. Vaccine-targeted HPV genotypes were detected in only 13 (1.7%) women: 11 HPV 16 (six vaccinated after sexual debut, five unvaccinated) and two HPV 6. Prevalence of any of HPV 31/33/45 collectively was 2.9%, varying significantly by vaccination status (fully 2.0%, unvaccinated 6.8%; p = 0.01). Vaccination rates among the sexually-active cohort were high, with 65.6%, 71.6% and 74.2% of participants having received three, at least two or at least one dose of vaccine, respectively. Of women self-reporting HPV vaccination, the NHVPR confirmed one or more doses were received in 90%. Strong associations were observed between vaccination status, age, language spoken at home and country of birth, as well as between HPV detection and the number of male sexual partners. CONCLUSION: Surveillance five to eight years' post-initiation of a national HPV vaccination program demonstrated a consistent and very low prevalence of vaccine-related HPV genotypes and some evidence of cross protection against related types amongst vaccine-eligible women from Victoria, Australia.
OBJECTIVES: The VACCINE [Vaccine Against Cervical Cancer Impact and Effectiveness] study evaluated the prevalence of quadrivalent vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst young women of vaccine-eligible age. METHODS: Between October 2011 - June 2015, women aged 18-25 years from Victoria, Australia, were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire and provided a self-collected vaginal swab for HPV DNA detection and genotyping (Linear Array HPV genotyping assay). Self-reported HPV vaccination details were verified with the National HPV Vaccination Program Register (NHVPR). RESULTS: Of 1223 who agreed to participate, 916 (74.9%) completed the survey and, for 1007 (82.3%) sexually-active participants, 744 (73.9%) returned the self-collected swab, of which 737 contained detectable DNA. 184/737 (25.0%) were positive for HPV. Vaccine-targeted HPV genotypes were detected in only 13 (1.7%) women: 11 HPV 16 (six vaccinated after sexual debut, five unvaccinated) and two HPV 6. Prevalence of any of HPV 31/33/45 collectively was 2.9%, varying significantly by vaccination status (fully 2.0%, unvaccinated 6.8%; p = 0.01). Vaccination rates among the sexually-active cohort were high, with 65.6%, 71.6% and 74.2% of participants having received three, at least two or at least one dose of vaccine, respectively. Of women self-reporting HPV vaccination, the NHVPR confirmed one or more doses were received in 90%. Strong associations were observed between vaccination status, age, language spoken at home and country of birth, as well as between HPV detection and the number of male sexual partners. CONCLUSION: Surveillance five to eight years' post-initiation of a national HPV vaccination program demonstrated a consistent and very low prevalence of vaccine-related HPV genotypes and some evidence of cross protection against related types amongst vaccine-eligible women from Victoria, Australia.
Authors: Chelse Spinner; Lili Ding; David I Bernstein; Darron R Brown; Eduardo L Franco; Courtney Covert; Jessica A Kahn Journal: Pediatrics Date: 2019-01-22 Impact factor: 7.124
Authors: Suzanne M Garland; Wayne Dimech; Peter Collignon; Louise Cooley; Graeme R Nimmo; David W Smith; Rob Baird; William Rawlinson; Anna-Maria Costa; Geoff Higgins Journal: J Pathol Clin Res Date: 2018-09-11
Authors: Emilien Jeannot; Manuella Viviano; Charlotte de Pree; Mona Amadane; Emmanuel Kabengele; Pierre Vassilakos; Patrick Petignat Journal: Int J Environ Res Public Health Date: 2018-07-09 Impact factor: 3.390
Authors: Julia Ml Brotherton; Alison Budd; Christopher Rompotis; Natasha Bartlett; Michael J Malloy; Rachael L Andersen; Kim Ar Coulter; Peter W Couvee; Nerida Steel; Gail H Ward; Marion Saville Journal: Papillomavirus Res Date: 2019-07-15
Authors: Maryam Shahmanesh; Guy Harling; Cordelia E M Coltart; Heather Bailey; Carina King; Jo Gibbs; Janet Seeley; Andrew Phillips; Caroline A Sabin; Robert W Aldridge; Pam Sonnenberg; Graham Hart; Mike Rowson; Deenan Pillay; Anne M Johnson; Ibrahim Abubakar; Nigel Field Journal: Lancet Infect Dis Date: 2020-05-07 Impact factor: 25.071